Edition:
United States

Nordic Nanovector ASA (NANOV.OL)

NANOV.OL on Oslo Stock Exchange

78.80NOK
5:35am EST
Change (% chg)

kr4.20 (+5.63%)
Prev Close
kr74.60
Open
kr75.15
Day's High
kr79.35
Day's Low
kr75.15
Volume
195,848
Avg. Vol
197,103
52-wk High
kr93.00
52-wk Low
kr37.26

Latest Key Developments (Source: Significant Developments)

Nordic Nanovector Comprehensive Loss For Q3 At NOK 75.4 Mln
Tuesday, 6 Nov 2018 01:00am EST 

Nov 6 (Reuters) - Nordic Nanovector ASA ::REVENUES FOR Q3 AMOUNTED TO NOK 0 (NOK 0.1 MILLION)..OTAL OPERATING EXPENSES FOR Q3 WERE NOK 76.9 MILLION (NOK 72.7 MILLION).COMPREHENSIVE LOSS FOR Q3 AMOUNTED TO NOK 75.4 MILLION (LOSS OF NOK 85.9 MILLION).IS CONFIDENT THAT BETALUTIN® COULD BECOME AN ATTRACTIVE AND CONVENIENT THERAPEUTIC OPTION.CURRENT CASH RESOURCES ARE EXPECTED TO BE SUFFICIENT TO REACH DATA READ-OUT FROM PARADIGME IN 1H 2020..NORDIC NANOVECTOR - CURRENT CASH RESOURCES ARE EXPECTED TO BE SUFFICIENT TO REACH DATA READ-OUT FROM PARADIGME IN 1H 2020.  Full Article

Nordic Nanovector Q1 Operating Loss Q1 At NOK 82.3 Million
Wednesday, 30 May 2018 01:00am EDT 

May 30 (Reuters) - Nordic Nanovector ASA ::REVENUES IN Q1 2018 AMOUNTED TO NOK 0 (NOK 0.1 MILLION)..TOTAL OPERATING EXPENSES FOR Q1 WERE NOK 82.3 MILLION (NOK 65.8 MILLION)..OPERATING LOSS FOR Q1 WAS NOK 82.3 MILLION (LOSS OF NOK 65.7 MILLION)..COMPREHENSIVE LOSS FOR Q1 WAS NOK 90.7 MILLION (LOSS OF NOK 55.8 MILLION)..CURRENT CASH RESOURCES ARE EXPECTED TO BE SUFFICIENT TO REACH DATA READ-OUT FROM PARADIGME IN 1H 2020..RESEARCH AND DEVELOPMENT EXPENSES ACCOUNTED FOR 76.2 % OF TOTAL OPERATING EXPENSES IN Q1 2018 (72.2 %).  Full Article

Nordic Nanovector Appoints Tone Kvåle As Interim Chief Executive Officer
Friday, 20 Apr 2018 08:49am EDT 

April 20 (Reuters) - Nordic Nanovector ASA ::NORDIC NANOVECTOR APPOINTS TONE KVÅLE AS INTERIM CHIEF EXECUTIVE OFFICER.APPOINTMENT IS MADE TO CONFORM TO NORWEGIAN COMPANIES LAW. A SEARCH FOR A FULL-TIME CEO IS PROGRESSING..  Full Article

Nordic Nanovector's ex-CEO bought 10,000 shares
Thursday, 5 Apr 2018 07:42am EDT 

April 5 (Reuters) - Nordic Nanovector ASA ::‍LUIGI COSTA, WHO RESIGNED AS CEO ON WEDNESDAY, HAS ON APRIL 5 PURCHASED 10,000 SHARES IN NORDIC NANOVECTOR ASA AT AN AVERAGE SHARE PRICE OF NOK 43.56​.‍FOLLOWING THIS TRANSACTION, LUIGI COSTA OWNS 91,115 SHARES IN COMPANY AND HOLDS 965,171 OPTIONS AND RELATED WARRANTS​.  Full Article

Nordic Nanovector Q4 Comprehensive Loss At NOK ‍87.6​ Mln
Tuesday, 27 Feb 2018 01:00am EST 

Feb 27 (Reuters) - NORDIC NANOVECTOR ASA ::Q4 TOTAL REVENUE NOK ‍0.1​ VERSUS NOK 0.1 MILLION YEAR AGO.Q4 COMPREHENSIVE LOSS NOK ‍87.6​ MILLION VERSUS LOSS NOK 59.3 MILLION YEAR AGO.  Full Article

Nordic Nanovector Q3 comprehensive loss widens to NOK 85.9 mln​
Wednesday, 22 Nov 2017 01:03am EST 

Nov 22 (Reuters) - NORDIC NANOVECTOR ASA ::‍REVENUES FOR Q3 AMOUNTED TO NOK 0.1 MILLION (NOK 0.1 MILLION)​.‍TOTAL OPERATING EXPENSES FOR Q3 WERE NOK 72.7 MILLION (NOK 50.4 MILLION)​.‍COMPREHENSIVE LOSS FOR Q3 AMOUNTED TO NOK 85.9 MILLION (LOSS OF NOK 61.3 MILLION)​.  Full Article

Nordic Nanovector says its share capital is NOK 9,808,880.40 divided into 49,044,402 shares
Wednesday, 30 Aug 2017 05:45am EDT 

Aug 30 (Reuters) - NORDIC NANOVECTOR ASA ::SAYS ITS SHARE CAPITAL IS NOK 9,808,880.40 DIVIDED INTO 49,044,402 SHARES, EACH WITH A NOMINAL OF NOK 0.20.  Full Article

Nordic Nanovector Q2 comprehensive widens to NOK 66.3 mln
Wednesday, 23 Aug 2017 01:00am EDT 

Aug 23 (Reuters) - NORDIC NANOVECTOR ASA :REVENUES FOR Q2 AMOUNTED TO NOK 0.1 MILLION (NOK 0.1 MILLION).COMPREHENSIVE LOSS FOR Q2 AMOUNTED TO NOK 66.3 MILLION (LOSS OF NOK 51.1 MILLION).  Full Article

Nordic Nanovector: Single dose Betalutin still shows promising efficacy and safety in recurrent iNHL
Wednesday, 14 Jun 2017 06:00am EDT 

June 14 (Reuters) - NORDIC NANOVECTOR ASA ::SINGLE DOSE BETALUTIN® CONTINUES TO SHOW PROMISING EFFICACY AND SAFETY IN RECURRENT INDOLENT NHL PATIENTS.SINGLE DOSE BETALUTIN® CONTINUES TO SHOW PROMISING EFFICACY AND SAFETY IN RECURRENT INDOLENT NHL PATIENTS.NORDIC NANOVECTOR - DATA CONTINUE TO SUPPORT COMPANY'S STRATEGY IN BETALUTIN'S DEVELOPMENT AND INTENT TO INITIATE OUR PIVOTAL PHASE 2 PARADIGME STUDY, IN SECOND HALF OF 2017.64% OVERALL RESPONSE RATE (ORR) AND 28% COMPLETE RESPONSES (CR) IN 47 EVALUABLE PATIENTS.  Full Article

Nordic Nanovector Q1 comprehensive loss NOK 55.8 million
Wednesday, 24 May 2017 01:00am EDT 

May 24 (Reuters) - NORDIC NANOVECTOR ASA :REVENUES IN Q1 2017 AMOUNTED TO NOK 0.078 MILLION (NOK 0.078 MILLION).COMPREHENSIVE LOSS FOR Q1 AMOUNTED TO NOK 55.8 MILLION (LOSS OF NOK 64.1 MILLION).TOTAL OPERATING EXPENSES FOR Q1 WERE NOK 65.8 MILLION (NOK 52.7 MILLION).CURRENT CASH RESOURCES ARE EXPECTED TO BE SUFFICIENT TO TAKE COMPANY BEYOND A FIRST REGULATORY SUBMISSION FOR BETALUTIN® IN FL IN FIRST HALF OF 2019.  Full Article

NORWEGIAN STOCKS-Down on rate outlook, Scatec drops after share issue

OSLO, June 14 (Reuters) - * Norwegian shares traded down on Thursday * Global markets dented by outlook for higher interest rates and weaker data from China * Oslo's benchmark index fell 0.24 pct, or -2.19 points, to 893.81 points and was up by 10.01 pct year-to-date * The broader Oslo All Share Index was down 0.14 percent * Brent crude futures, a trigger for the oil heavy Oslo Bourse, fell $-0.19 to $76.55 a barrel * Among the biggest firms on the Oslo Bourse, Equinor rose 0.28 pct, Telenor fel